A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers.
Document Type
Article, Non peer-reviewed
Publication Date
1-23-2012
Abstract
A feasibility study was conducted to pilot test the ability of 5 sites to recruit, treat, and retain opioid-dependent offenders in a trial of extended-release injectable naltrexone (XR-NTX). The participants, 61 previously opioid-dependent individuals under legal supervision in the community, received up to 6 monthly injections of Depotrex brand naltrexone and completed a 6-month follow-up interview. Six-month outcomes showed that those who completed treatment had significantly fewer opioid-positive urines and were less likely to have been incarcerated than those who had not completed treatment. The findings indicate that XR-NTX holds promise as a feasible, effective treatment option for opioid-dependent offenders.
Recommended Citation
Coviello, Donna M.; Cornish, James W.; Lynch, Kevin G.; Boney, Tamara Y.; Clark, Cynthia A.; Lee, Joshua D.; Friedmann, Peter D.; Nunes, Edward V.; Kinlock, Timothy W.; Gordon, Michael S.; Schwartz, Robert P.; Nuwayser, Elie S.; and O'Brien, Charles P., "A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers." (2012). All Scholarly Works. 8377.
https://scholarlycommons.libraryinfo.bhs.org/all_works/8377
PMID
22263713